好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | C81 - Headache in Special Populations

Monday 04/15/24
01:00 PM - 03:00 PM MDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA
Headache
Participants should be able to describe, and define when appropriate, special populations in headache medicine; discuss key epidemiology of special populations in headache medicine; and define intersectionality and articulate its importance in the care of special populations.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Quality Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Case-based, Didactic

Program Evaluations

Event Timeline
01:00 PM - 01:15 PM MDT Introduction Headache in Special Populations
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA
01:15 PM - 01:30 PM MDT Speaker Case & Presentation: Headache Special Population—Individuals with Severe Cognitive, Mental, and/or Physical Impairments and the Caregiver
Susan M. Woolner, CPXP
01:30 PM - 01:35 PM MDT Q&A Questions & Answers
Susan M. Woolner, CPXP
01:35 PM - 01:50 PM MDT Speaker Case & Presentation: Headache Special Population: Children
Christina L. Szperka, MD
01:50 PM - 01:55 PM MDT Q&A Questions & Answers
Christina L. Szperka, MD
01:55 PM - 02:10 PM MDT Speaker Case & Presentation: Headache Special Population: Rural Populations
David B. Watson, MD, FAAN
02:10 PM - 02:15 PM MDT Q&A Questions & Answers
David B. Watson, MD, FAAN
02:15 PM - 02:25 PM MDT Q&A Panelists Questions & Answers
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA, Susan M. Woolner, CPXP, David B. Watson, MD, FAAN
02:25 PM - 02:35 PM MDT Speaker A Brief Exploration of Intersectionality
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA
02:35 PM - 02:55 PM MDT Discussion Final Case Presentation with Audience Participation and Panelist Discussion
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA, Susan M. Woolner, CPXP, David B. Watson, MD, FAAN
02:55 PM - 03:00 PM MDT Closing Remarks Closing Remarks
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA
Faculty Disclosures
Larry "LC" Charleston, IV IV, MD, MSc, FAHS, FANA Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Charleston has stock in Mi-Helper Inc.. Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member with Clinical Neurological Society of America that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Chair, EDI Advisory Committee (Non-voting Board Member) with American Headache Society that is relevant to AAN interests or activities.
Susan M. Woolner, CPXP Ms. Woolner has nothing to disclose.
David B. Watson, MD, FAAN Dr. Watson has nothing to disclose.
Christina L. Szperka, MD The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Upsher Smith. The institution of Dr. Szperka has received research support from NINDS. The institution of Dr. Szperka has received research support from PCORI. The institution of Dr. Szperka has received research support from International Headache Society.